Clinical effectiveness and safety of tazobactam/piperacillin 4.5 g for the prevention of febrile infectious complication after prostate biopsy |
| |
| Affiliation: | 1. Department of Urology, Gifu University Hospital, Japan;2. Department of Urology, University of Occupational and Environmental Health, Japan;3. Division of Urology, Kobe University Graduate School of Medicine, Japan;4. Department of Urology, Chugoku Rosai Hospital, Japan Labour Health and Welfare Organization, Japan;5. Department of Urology, Shinko Hospital, Japan;6. Department of Urology, Kizawa Memorial Hospital, Japan;7. Department of Urology, Hyogo College of Medicine, Japan;8. Department of Urology, Hiroshima University Institute of Biomedical and Health Sciences, Japan;9. Japanese Research Group for Urinary Tract Infection, Japan;1. Department of Medical Biotechnologies, University of Siena, Siena, Italy;2. University Division of Infectious Diseases, Hospital Department of Specialized and Internal Medicine, Siena, Italy;3. Unit of Neuroimaging and Neurointervention, Hospital Department of Neurological and Sensorineural Sciences, University Hospital of Siena, Siena, Italy;4. Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy;5. Clinical Microbiology and Virology Unit, Florence Careggi University Hospital, Florence, Italy;1. Department of Neurosurgery, Tsukuba Medical Center Hospital, Ibaraki, Japan;2. Division of Infectious Diseases, Department of Medicine, Tsukuba Medical Center Hospital, Ibaraki, Japan;3. Department of Microbiology, Tokyo Medical University, Tokyo, Japan;4. Department of Clinical Microbiology, Miroku Medical Laboratory Inc., Nagano, Japan;5. Department of Infectious Diseases, Ibaraki Medical Center, Tokyo Medical University, Tokyo, Japan;6. Department of Neurosurgery, University of Tsukuba Hospital, Ibaraki, Japan;1. Division of Paediatric Urology, The Hospital for Sick Children and University of Toronto, Toronto, Ontario, Canada;2. Urology Division, Department of Surgery, King Saud University, King Khalid University Hospital, College of Medicine, Riyadh, Saudi Arabia;1. Clinical Pharmacology Statistics, Novartis Pharma, Basel, Switzerland;2. Statistical Methods and Research, Genentech Inc., USA;2. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden;1. Compass Oncology, Tualatin, OR;2. Texas Oncology at Baylor Charles A. Sammons Cancer Center, Dallas, TX;3. McKesson Specialty Health, The Woodlands, TX;4. Comprehensive Cancer Centers of Nevada, Las Vegas, NV |
| |
| Abstract: | ![]()
We investigated the clinical effectiveness and safety of tazobactam/piperacillin (TAZ/PIPC) in a 1:8 ratio, a β-lactamase inhibitor with penicillin antibiotic, for the prevention of febrile infectious complication after prostate biopsy. Each patient received a single dose of TAZ/PIPC 4.5 g, 30 min before the biopsy in Group 1 or TAZ/PIPC 4.5 g twice, once 30 min before and once after the biopsy (just before discharge or 5 h after the biopsy), in Group 2. Estimation of efficacy was performed within 1-month after prostate biopsy. Clinical diagnosis of febrile infectious complication was based on a body temperature elevation greater than 38 °C. Infectious complication after prostate biopsy was detected in 2.5% (4/160 patients) in Group 1 and in 0.45% (2/442 patients) in Group 2. All of the patients with febrile infectious complication had risk factors: 5 patients had voiding disturbance, 2 patients had diabetes mellitus and 1 patient had steroid dosing. In group 1, 88 patients had at least one risk factor and 72 patients had no risk factors. Of the patients with a risk factor, 4 had febrile infectious complication after prostate biopsy, but there was no significant difference between the two groups. In group 2, 87 patients had at least one risk factor and 255 patients had no risk factors. The patients with a risk factor had febrile infectious complication significantly more frequently than did patients without a risk factor (P = 0.038). Therefore, TAZ/PIPC appears to be effective as preoperative prophylaxis against the occurrence of febrile infectious complication after prostate biopsy. |
| |
| Keywords: | Prostate biopsy Prophylaxis Infectious complication Tazobactam/piperacillin |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
